United Spirits to buy out Greater Than gin maker Nao Spirits in a ₹110 cr deal
The USL board approved the acquisition of an additional stake in Nao Spirits, which owns gin brands like Greater Than and Hapusa, on Wednesday.
The company, which already holds 30% in the business, will buy 37,683 equity shares from existing shareholders in two tranches for around ₹ 53.8 crore.
It will simultaneously invest approximately ₹ 56 crore via a fresh subscription of 31,820 equity shares and 27,577 compulsorily convertible preference shares (CCPS), it said in the filing.
Following the completion of the first tranche and the new issuance, USL will own around 97.07% of Nao Spirits' paid-up capital on a fully diluted basis.
The second tranche of the share purchase, to be completed later, will raise its ownership to 100%, making the craft spirits maker a wholly owned subsidiary of the Diageo arm.
The USL board has also authorized a further investment of up to ₹ 20 crore in the alco-bev startup through equity or CCPS to support its working capital and business requirements.
USL first acquired a stake in the company in March 2022 and has since completed a gradual buyout. Nao Spirits entered the premium gin market in 2016.
'Ventures, our investment arm, is dedicated to strengthening our portfolio by investing in disruptive alco-bev startups. The acquisition represents a pivotal step in exploring future growth opportunities in Indian craft spirits…,' said Praveen Someshwar, managing director and chief executive, Diageo India (USL).
In September 2024, Mint reported that Diageo, the world's largest spirits company, planned to pour $100 million ( ₹ 840 crore then) into the country over the next three years to grow its premium portfolio and develop new products tailored to local tastes.
Its chief executive Debra Crew, speaking to Mint, said India was now emerging as a key innovation hub for the company, where products like the homegrown single malt Godawan are first tested and refined before being launched in global markets.
Crew added that Diageo was also open to investing in Indian craft spirit brands, citing the country's growing pool of young, affluent consumers. In addition to its investment in Nao Spirits, Diageo has set up a ₹ 45 crore innovation centre in Goa to support research and development of premium beverages.
Data from international drinks consultancy IWSR showed that gin had a rapid ascent in the country before levelling off in 2024. The category grew a modest 1% in volume, signalling that the enthusiasm around homegrown craft gins may be cooling.
According to industry estimates, at its peak two years ago, the craft gin segment sold roughly 350,000 cases annually. Insiders told Mint that those numbers have now plateaued, an indication that consumer interest may be shifting toward other white spirits.
For the year ending 31 March 2025, Diageo India posted gross revenues of ₹ 26,780 crore, marking a 5.4% year-on-year increase. In the March quarter alone, net sales rose 10.5% to ₹ 2,946 crore, driven by a strong portfolio performance and the reopening of trade in Andhra Pradesh.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
29 minutes ago
- Business Standard
Brigade Hotels signs agreement to build 6 new Marriott hotels by FY30
Bengaluru-based Brigade Hotel Ventures (BHV), which recently listed on the bourses, on Wednesday signed a multi-deal agreement with global hotel chain Marriott International to develop six hotels for the company. Coming up in four key southern cities — Chennai, Bengaluru, Thiruvananthapuram and Kochi — the move will add about 940 keys to BHV's portfolio in the country, taking it to 3,300 keys. The new hotels will be classified under the Fairfield by Marriott, JW Marriott, Courtyard by Marriott and The Ritz-Carlton brands. 'With this signing, Brigade reinforces its nearly 15-year partnership with Marriott, further strengthening a successful relationship and bringing the total to eight hotels with Marriott, totalling 1,388 keys,' the company stated in a release. While the Courtyard by Marriott offering at Chennai World Trade Center with 45 keys is expected to open in financial year 2027 (FY27), the Fairfield by Marriott Bengaluru International Airport (224 keys) and Fairfield by Marriott Bengaluru Brigade Valencia (151 keys) are set to open in FY28. Additionally, the JW Marriott at OMR Chennai with 250 keys, the 70-key all-villa Ritz-Carlton Vaikom Island in Kerala, and the mixed-use Thiruvananthapuram Marriott Hotel World Trade Center with 200 keys are set to open in FY30. 'Our growth strategy focuses on being present where our guests want us to be. Today's signed agreement underscores our long-standing relationship with Brigade Hotel Ventures Limited, and leveraging the strength of our diverse brand portfolio, we are confident these new developments will meet the needs of travellers, for every trip purpose,' said Rajeev Menon, president, Asia Pacific excluding China at Marriott International. Last month, the NASDAQ-listed global hospitality major had signed an agreement with Blackstone-backed Ventive Hospitality for six new hotels — at Varanasi in Uttar Pradesh, Mundra in Gujarat, and Pune and Navi Mumbai in Maharashtra — by 2030. The American hospitality chain currently has over 155 hotels and over 29,000 rooms in more than 40 Indian cities. Earlier this year, Anthony Capuano, president and chief executive officer of Marriott International, had stated that he expects India to become its third-largest market within five years. "We will continue the momentum we enjoy in the upper, upscale, and luxury segment. We will also look at the lower end of the chain scales and create more opportunities for the value-conscious inbound international traveller and the domestic traveller," Capuano had said.
Economic Times
29 minutes ago
- Economic Times
Muthoot Finance Q1 Results: Standalone profit surges 90% to Rs 2,046 crore on strong loan growth
Indian gold loan financier Muthoot Finance reported a bigger-than-expected 90% surge in first-quarter profit on Wednesday, aided by higher loan demand as prices of the precious metal soared. ADVERTISEMENT Muthoot Finance reported a standalone profit of Rs 2,046 crore ($233.91 million) for the April-June quarter, above analysts' estimate of Rs 1,624 crore, per data compiled by LSEG. Gold prices hit multiple record highs during the quarter. This benefits gold financiers as higher prices increase the collateral value, allowing borrowers to secure larger loans for the same amount of gold. Additionally, tighter lending in the unsecured segment prompted people to shift to gold loans as an alternative source of funds, analysts said. Muthoot Finance's standalone loan assets under management rose 42% year-on-year to 1.2 trillion rupees at the end of the quarter, and interest income jumped about 53% to 55.92 billion rupees. "We are well-positioned to sustain strong growth through fiscal 2026 and beyond," Managing Director George Alexander Muthoot said in a statement. ADVERTISEMENT The company also approved equity infusion of 5 billion rupees and 2 billion rupees in its units, Muthoot Money and Muthoot Homefin, respectively. Unlock 500+ Stock Recos on App (You can now subscribe to our ETMarkets WhatsApp channel)
Mint
29 minutes ago
- Mint
Nifty Pharma index rises 1.9%: Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?
Stock Market Today: The Nifty Pharma index gained 1.9% during the intraday trades on Wednesday. Alkem and Zydus stood among key gainers that led the rally The Nifty Pharma Index gained almost 2% during the intraday trade on Wednesday amid a relief rally in the Indian stock market. The Nifty Pharma Index opened at 21,803.45 levels, higher than the previous day's closing price of 21,753.50. It continued to gain further to an intraday high of 22,171.05, which meant gains of almost 2% over the previous day's close. Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and Abbott India were among the key gainers that led to the rise in the Nifty Pharma pack. The US market remains critical for many Indian pharma companies. Sun Pharmaceuticals, Lupin , Dr. Reddy's, Aurobindo, Cipla, and many more derive a significant part of revenues from the US markets. Thus the danger of a 50% tax on pharmaceuticals looms, and this clearly poses a risk to the profitability of Indian pharmaceutical businesses, which rely on the US market for 30-50% of their sales. Most of these US revenues, however, come from the generic drug segment. Silver lining The silver lining remains as India remains cost-competitive compared to both the US and global peers, which should help mitigate some risks, said Ajit Banerjee, president and chief investment officer at Shriram Life Insurance. The domestic Indian pharma market (50% of the Indian pharmaceutical market) will remain unaffected by tariffs. Within the US, the impact on the generic formulations market is still uncertain, though Indian players already operate on thin margins. Tariffs could increase the drug shortages by eliminating competition in a market where pricing pressures are already intense, which could be a positive for Indian companies over the mid- to long-term, highlighted Banerjee While the recent executive order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. Any tariff action will depend on the outcome of the ongoing investigation under Section 232 of the Trade Expansion Act of 1962. Even if the India pharma tariff question is answered, Kotak Institutional expect the uncertainty to persist around whether the anticipated pharma tariffs (post the Section 232 investigation) would add to the country-specific one, definition of pharma/pharma products and then eventually how much of the tariffs are passed on and rolled back Bannerjee believes the US can either bring manufacturing back home or reduce drug prices, but not both simultaneously. Even before tariffs are finalized, the uncertainty can lead to delays in order commitments and impact sector sentiment and stock price thereby. The sector currently trades at a 1Y forward P/E of 29.7 times, above its 10-year average of 26.7x. We see tariff-induced volatility as a chance for investors to accumulate quality pharma stocks on dips, said Banerjee. Nifty Pharma has witnessed two weeks of selling pressure, especially after the recent U.S. tariff developments, as per analysts. The Pharma Index was trading near a support level on the daily time frame, where a pause in the decline was expected in the coming days, potentially leading the index towards 21,998. The outlook remains negative as long as the index fails to sustain above 22,380. On the downside, a break below 21,240 could push the index further towards the 20,380–20,140 zone, as per Kunal Kamble, Sr. Technical Research Analyst at Bonanza *
